Business Description
Betta Pharmaceuticals Co Ltd
ISIN : CNE100002DD9
Share Class Description:
SZSE:300558: Class ACompare
Compare
Traded in other countries / regions
300558.China IPO Date
2016-11-07Description
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.35 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.41 | |||||
| Debt-to-EBITDA | 4.6 | |||||
| Interest Coverage | 10.58 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.62 | |||||
| Beneish M-Score | -3.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.4 | |||||
| 3-Year EBITDA Growth Rate | -8.5 | |||||
| 3-Year EPS without NRI Growth Rate | -8.9 | |||||
| 3-Year FCF Growth Rate | -64.2 | |||||
| 3-Year Book Growth Rate | 7.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 57.59 | |||||
| Future 3-5Y Total Revenue Growth Rate | 24.71 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.58 | |||||
| 9-Day RSI | 56.1 | |||||
| 14-Day RSI | 56.47 | |||||
| 6-1 Month Momentum % | 63.03 | |||||
| 12-1 Month Momentum % | 3.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.86 | |||||
| Quick Ratio | 0.7 | |||||
| Cash Ratio | 0.46 | |||||
| Days Inventory | 240.84 | |||||
| Days Sales Outstanding | 38.1 | |||||
| Days Payable | 488.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.31 | |||||
| Dividend Payout Ratio | 0.17 | |||||
| 3-Year Dividend Growth Rate | -28.3 | |||||
| Forward Dividend Yield % | 0.31 | |||||
| 5-Year Yield-on-Cost % | 0.27 | |||||
| 3-Year Average Share Buyback Ratio | -0.4 | |||||
| Shareholder Yield % | -0.94 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.2 | |||||
| Operating Margin % | 17 | |||||
| Net Margin % | 16.67 | |||||
| FCF Margin % | 11.27 | |||||
| ROE % | 8.47 | |||||
| ROA % | 5.02 | |||||
| ROIC % | 5.42 | |||||
| ROC (Joel Greenblatt) % | 19.18 | |||||
| ROCE % | 6.75 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 50.64 | |||||
| Forward PE Ratio | 30.53 | |||||
| PE Ratio without NRI | 55.37 | |||||
| Shiller PE Ratio | 62.73 | |||||
| PEG Ratio | 4.94 | |||||
| PS Ratio | 8.46 | |||||
| PB Ratio | 4.1 | |||||
| Price-to-Tangible-Book | 11.15 | |||||
| Price-to-Free-Cash-Flow | 74.37 | |||||
| Price-to-Operating-Cash-Flow | 19.66 | |||||
| EV-to-EBIT | 48.26 | |||||
| EV-to-EBITDA | 48.26 | |||||
| EV-to-Revenue | 8.86 | |||||
| EV-to-FCF | 78.68 | |||||
| Price-to-Projected-FCF | 10.74 | |||||
| Price-to-DCF (Earnings Based) | 4.8 | |||||
| Price-to-DCF (FCF Based) | 6.45 | |||||
| Price-to-Graham-Number | 5.24 | |||||
| Earnings Yield (Greenblatt) % | 2.07 | |||||
| FCF Yield % | 1.35 | |||||
| Forward Rate of Return (Yacktman) % | -4.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Betta Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 2,757.287 | ||
| EPS (TTM) (Â¥) | 1.09 | ||
| Beta | 2.11 | ||
| Volatility % | 53.39 | ||
| 14-Day RSI | 56.47 | ||
| 14-Day ATR (Â¥) | 2.210138 | ||
| 20-Day SMA (Â¥) | 55.078 | ||
| 12-1 Month Momentum % | 3.38 | ||
| 52-Week Range (Â¥) | 30.43 - 59 | ||
| Shares Outstanding (Mil) | 418.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Betta Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Betta Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Betta Pharmaceuticals Co Ltd Frequently Asked Questions
What is Betta Pharmaceuticals Co Ltd(SZSE:300558)'s stock price today?
The current price of SZSE:300558 is ¥55.20. The 52 week high of SZSE:300558 is ¥59.00 and 52 week low is ¥30.43.
When is next earnings date of Betta Pharmaceuticals Co Ltd(SZSE:300558)?
The next earnings date of Betta Pharmaceuticals Co Ltd(SZSE:300558) is .
Does Betta Pharmaceuticals Co Ltd(SZSE:300558) pay dividends? If so, how much?
The Dividend Yield %  of Betta Pharmaceuticals Co Ltd(SZSE:300558) is 0.31% (As of Today), Highest Dividend Payout Ratio of Betta Pharmaceuticals Co Ltd(SZSE:300558) was 3.57. The lowest was 0.11. And the median was 0.28. The  Forward Dividend Yield % of Betta Pharmaceuticals Co Ltd(SZSE:300558) is 0.31%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers